Reviewed by Michael Gill, B. Sc.
8 Forteo Clinical Trials Near Me
Top Cities for Forteo Clinical Trials
Image of Lexington in Kentucky.
2Active Trials
University of KentuckyTop Active Site
Image of West Haverstraw in New York.
West Haverstraw
2Active Trials
Helen Hayes HospitalTop Active Site
Forteo Clinical Trials by Phase of Trial
Phase 2 Forteo Clinical Trials
1Active Forteo Clinical Trials
1Number of Unique Treatments
0Number of Active Locations
Most Recent Forteo Clinical Trials

What Are Forteo Clinical Trials?

Forteo clinical trials are research studies in which people participate in a new treatment for osteoporosis or Paget's disease. Researchers conduct clinical trials to test whether a new treatment is safe and effective for humans.

If you are considering participating in a Forteo clinical trial, you must understand the process and what you can expect.

Why is Forteo Being Studied in Clinical Trials?

The FDA has approved Forteo for treating osteoporosis in postmenopausal women and Paget's disease. However, researchers are still studying Forteo for other potential uses.

For example, clinical trials are currently underway to study Forteo for treating men with osteoporosis and preventing fractures in people with kidney disease. It is also being studied for its potential to treat osteoporosis in premenopausal women.

How Does Forteo Treatment Work?

Forteo is a manufactured form of parathyroid hormone (PTH). PTH is a hormone that helps regulate calcium and phosphorus levels in the body.

Forteo increases bone formation and slows down bone breakdown. It also helps the body absorb calcium from the diet and maintain calcium levels in the blood.

It's administered by injection under the skin once a day. However, an investigational once-weekly injection for people with osteoporosis is being studied in clinical trials.

After injection, Forteo is slowly absorbed into the bloodstream, where it stays for 24 hours. It then leaves the body through urine.

Forteo is being studied and compared to similar drugs such as bisphosphonates (alendronate and risedronate) and denosumab. Recent testing has shown that Forteo may be more effective than these other drugs for treating osteoporosis.

What Are Some of the Breakthrough Clinical Trials Involving Forteo?

Some of the most important clinical trials for Forteo have been for treating and preventing osteoporosis.

2013: In one major trial, postmenopausal women with osteoporosis were given either Forteo or Forteo and Denosumab for two years. The results showed that the women taking Forteo and Denosumab had significantly more bone density than those who only took Forteo.

2020: In another study, Forteo (teriparatide) was more effective in another trial than alendronate. The results showed after 12 weeks, there were improvements in pain and quality of life for osteoporotic vertebral fractures.

2020: this study showed that Forteo was effective for premenopausal Idiopathic Osteoporosis for bone remodeling and density. The study proved that Forteo showed an increase in tissue-level bone formation rate (BFR) and showed improvements up to 82% in premenopausal women.

Who Are The Key Opinion Leaders On Forteo Clinical Trial Research?

Dr. Clifford J. Rosen is one of the world's leading experts on Forteo and has conducted many clinical trials for the drug. He is the Director of the Center for Clinical and Translational Research at the Maine Medical Center Research Institute.

Dr. Ethel Siris is another key opinion leader on Forteo clinical trials. Dr. Siris was the Director of the Toni Stabile Osteoporosis Center at Columbia University Medical Center. However, she is now on the Board of Trustees of the National Osteoporosis Foundation and the International Osteoporosis Foundation. She specializes in Endocrinology and internal medicine.

Dr. Elizabeth J. Shane is a Professor of Medicine and Vice Chair of Medicine for Clinical and Epidemiological Research at Columbia University. Her research focuses on research studies in endocrinology and internal medicine.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: October 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Hara T, Hijikata Y, Matsubara Y, Watanabe N. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. Cochrane Database Syst Rev. 2021 Jul 7;7:CD013424. doi: 10.1002/14651858.CD013424.pub2. Cosman F, Nieves JW, Roimisher C, Neubort S, McMahon DJ, Dempster DW, Lindsay R. Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women. Bone. 2019 Mar;120:246-253. doi: 10.1016/j.bone.2018.10.020. Epub 2018 Oct 21. Cosman F, McMahon D, Dempster D, Nieves JW. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. J Bone Miner Res. 2020 Feb;35(2):219-225. doi: 10.1002/jbmr.3850. Epub 2019 Oct 23.